Maxim Group analyst Jason McCarthy maintained a Buy rating on Gain Therapeutics (GANX – Research Report) yesterday and set a price target of $5.00.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Gain Therapeutics’ innovative approach and promising developments. The company is leveraging its AI-supported structural biology platform to discover novel allosteric binding sites, which sets it apart in the biotechnology field. Their lead candidate, GT-02287, is currently in clinical trials for Parkinson’s disease, and the recent initiation of the Phase 1b study marks a significant milestone.
The interim data expected by the second quarter of 2025 could act as a catalyst if the results are positive, particularly given the promising preclinical data showing improved GCase activity and other beneficial effects in models of Parkinson’s disease. Furthermore, the company’s ability to execute its development plans despite challenging market conditions demonstrates resilience and potential for future growth. These factors contribute to McCarthy’s optimistic outlook and the Buy rating for Gain Therapeutics’ stock.
McCarthy covers the Healthcare sector, focusing on stocks such as Medicus Pharma Ltd, SELLAS Life Sciences Group, and Mesoblast. According to TipRanks, McCarthy has an average return of -18.6% and a 25.86% success rate on recommended stocks.
In another report released on March 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.